Royal DSM, a global science-based company active in health, nutrition and materials, announces it has acquired BioCare Copenhagen A/S, based in Copenhagen (Denmark).
With the acquisition, DSM expands its offering in gut health ingredients with probiotics, an attractive market segment in nutritional ingredients, growing an estimated 7% per year. Financial details will not be disclosed at this time.
BioCare Copenhagen is a privately-held company founded in 2012, focused on probiotics and specialized in microbial actives with proven health benefits, targeting gastrointestinal disorders, metabolic disorders, infections, and immunity. The company offers high-quality white label probiotic supplements and complete product concepts with strong consumer appeal. BioCare Copenhagen has multi-market distribution agreements with a number of leading dietary supplements and pharmaceutical companies and has launched products in over 40 countries worldwide.
DSM already has a strong position in gut health solutions with its Culturelle® product range, the number-one-selling probiotic dietary supplement consumer brand globally, as well as with its ingredient brands Oatwell® and Tolerase®. The company sees further growth potential in gut health ingredients beyond the established indications for digestive health and immune health. Fields increasingly recognized as being impacted by the gut microbiome include the gut-brain axis, metabolic health and heart health. DSM’s ambition in addressing the gut microbiome and its portfolio of nutritional ingredients are very synergetic with BioCare Copenhagen’s approach and products, and the combination is well-catered to address the existing and emerging gut health areas.
Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.
Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.
Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.